$150 Million is the total value of Birchview Capital, LP's 0 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 11.1% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
CELG | Buy | CELGENE CORP | $69,475,000 | +7.7% | 699,648 | +0.3% | 46.29% | +18.0% |
AXDX | ACCELERATE DIAGNOSTICS INC | $40,553,000 | -18.8% | 2,183,795 | 0.0% | 27.02% | -11.1% | |
NBIX | NEUROCRINE BIOSCIENCES INC | $4,956,000 | +6.7% | 55,000 | 0.0% | 3.30% | +16.9% | |
EQM | Buy | EQM MIDSTRM PRTNERS LP LTDunit ltd partn | $3,311,000 | +48.2% | 101,250 | +102.5% | 2.21% | +62.3% |
QDEL | QUIDEL CORP | $2,997,000 | +3.5% | 48,844 | 0.0% | 2.00% | +13.3% | |
OXFD | Buy | OXFORD IMMUNOTEC GLOBAL PLC | $2,832,000 | +46.7% | 170,303 | +21.4% | 1.89% | +60.7% |
BMY | Buy | BRISTOL-MYERS SQUIBB CO | $2,383,000 | +19.4% | 47,000 | +6.8% | 1.59% | +30.9% |
VRML | Buy | VERMILLION INC | $1,683,000 | -39.4% | 3,221,933 | +3.2% | 1.12% | -33.7% |
DOVA | DOVA PHARMACEUTICALS INC | $1,398,000 | +98.3% | 50,000 | 0.0% | 0.93% | +117.2% | |
MASI | MASIMO CORP | $1,190,000 | -0.1% | 8,000 | 0.0% | 0.79% | +9.5% | |
BIIB | BIOGEN INC | $1,164,000 | -0.4% | 5,000 | 0.0% | 0.78% | +9.1% | |
VNDA | VANDA PHARMACEUTICALS INC | $1,062,000 | -5.8% | 80,000 | 0.0% | 0.71% | +3.4% | |
HROW | HARROW HEALTH INC | $1,012,000 | -35.4% | 180,000 | 0.0% | 0.67% | -29.2% | |
ARNA | ARENA PHARMACEUTICALS INC | $1,007,000 | -21.9% | 22,000 | 0.0% | 0.67% | -14.5% | |
GTHX | G1 THERAPEUTICS INC | $911,000 | -25.7% | 40,000 | 0.0% | 0.61% | -18.6% | |
AMRN | AMARIN CORP PLCspons adr new | $894,000 | -21.9% | 59,000 | 0.0% | 0.60% | -14.4% | |
MYGN | Buy | MYRIAD GENETICS INC | $859,000 | +54.5% | 30,000 | +50.0% | 0.57% | +69.2% |
DERM | DERMIRA INC | $767,000 | -33.1% | 120,000 | 0.0% | 0.51% | -26.8% | |
ALBO | ALBIREO PHARMA INC | $760,000 | -38.0% | 38,000 | 0.0% | 0.51% | -32.1% | |
XLRN | ACCELERON PHARMA INC | $738,000 | -3.8% | 18,672 | 0.0% | 0.49% | +5.6% | |
CORT | CORCEPT THERAPEUTICS INC | $707,000 | +26.7% | 50,000 | 0.0% | 0.47% | +38.9% | |
KPTI | KARYOPHARM THERAPEUTICS INC | $673,000 | +60.6% | 70,000 | 0.0% | 0.45% | +75.7% | |
ARVN | ARVINAS INC | $647,000 | -2.0% | 30,000 | 0.0% | 0.43% | +7.5% | |
T107PS | WRIGHT MEDICAL GROUP NV | $619,000 | -30.8% | 30,000 | 0.0% | 0.41% | -24.3% | |
DRNA | Sell | DICERNA PHARMACEUTICALS INC | $574,000 | -19.0% | 40,000 | -11.1% | 0.38% | -11.4% |
ICPT | INTERCEPT PHARMACEUTICALS INC | $551,000 | -16.5% | 8,300 | 0.0% | 0.37% | -8.5% | |
ODT | ODONATE THERAPEUTICS INC | $521,000 | -29.0% | 20,000 | 0.0% | 0.35% | -22.2% | |
VYGR | VOYAGER THERAPEUTICS INC | $516,000 | -36.8% | 30,000 | 0.0% | 0.34% | -30.8% | |
ACAD | Buy | ACADIA PHARMACEUTICALS INC | $504,000 | +88.8% | 14,000 | +40.0% | 0.34% | +107.4% |
PXD | PIONEER NATURAL RESOURCES CO | $478,000 | -18.3% | 3,800 | 0.0% | 0.32% | -10.4% | |
IMGN | IMMUNOGEN INC | $436,000 | +11.5% | 180,000 | 0.0% | 0.29% | +22.3% | |
XNCR | XENCOR INC | $415,000 | -17.5% | 12,300 | 0.0% | 0.28% | -9.5% | |
VCYT | Sell | VERACYTE INC | $378,000 | -56.9% | 15,767 | -48.8% | 0.25% | -52.7% |
SLNO | SOLENO THERAPEUTICS INC | $361,000 | -46.4% | 240,598 | 0.0% | 0.24% | -41.2% | |
KALV | New | KALVISTA PHARMACEUTICALS INC | $348,000 | – | 30,000 | +100.0% | 0.23% | – |
XBIT | Buy | XBIOTECH INC | $314,000 | +313.2% | 30,000 | +200.0% | 0.21% | +354.3% |
FOLD | AMICUS THERAPEUTICS INC | $305,000 | -35.7% | 38,000 | 0.0% | 0.20% | -29.5% | |
SIEN | SIENTRA INC | $259,000 | +5.3% | 40,000 | 0.0% | 0.17% | +15.3% | |
CLR | CONTINENTAL RESOURCES INC | $246,000 | -27.0% | 8,000 | 0.0% | 0.16% | -20.0% | |
LXRX | LEXICON PHARMACEUTICALS INC | $241,000 | -52.1% | 80,000 | 0.0% | 0.16% | -47.4% | |
MREO | Buy | MEREO BIOPHARMA GROUP PLCads | $231,000 | +92.5% | 77,570 | +63.1% | 0.15% | +111.0% |
ECA | Buy | ENCANA CORP | $228,000 | -6.6% | 49,550 | +4.3% | 0.15% | +2.7% |
CYTK | CYTOKINETICS INC | $114,000 | +0.9% | 10,000 | 0.0% | 0.08% | +10.1% | |
WKHS | WORKHORSE GROUP INC | $88,000 | +18.9% | 25,000 | 0.0% | 0.06% | +31.1% | |
TGTX | TG THERAPEUTICS INC | $84,000 | -35.4% | 15,000 | 0.0% | 0.06% | -29.1% | |
CFRX | Sell | CONTRAFECT CORP | $81,000 | -34.1% | 227,003 | -5.5% | 0.05% | -28.0% |
LTHM | LIVENT CORP | $67,000 | -2.9% | 10,000 | 0.0% | 0.04% | +7.1% | |
YTEN | YIELD10 BIOSCIENCE INC | $62,000 | -48.3% | 123,639 | 0.0% | 0.04% | -43.8% | |
BCRX | BIOCRYST PHARMACEUTICALS INC | $57,000 | -25.0% | 20,000 | 0.0% | 0.04% | -17.4% | |
GNMX | AEVI GENOMIC MEDICINE INC | $19,000 | -5.0% | 128,000 | 0.0% | 0.01% | +8.3% | |
EQT | Exit | EQT CORPORATION | $0 | – | -11,300 | -100.0% | -0.11% | – |
APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -8,000 | -100.0% | -0.12% | – |
NKTR | Exit | NEKTAR THERAPEUTICS | $0 | – | -9,500 | -100.0% | -0.21% | – |
ATRA | Exit | ATARA BIOTHERAPEUTICS INC | $0 | – | -20,000 | -100.0% | -0.24% | – |
ARRY | Exit | ARRAY BIOPHARMA INC | $0 | – | -168,000 | -100.0% | -4.73% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-12
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ACCELERATE DIAGNOSTICS INC | 36 | Q3 2023 | 34.6% |
QUIDELORTHO CORP | 36 | Q3 2023 | 8.6% |
MASIMO CORP | 36 | Q3 2023 | 2.2% |
PIONEER NATURAL RESOURCES CO (PXD) | 36 | Q3 2023 | 0.7% |
XENCOR INC | 35 | Q3 2023 | 0.4% |
NEUROCRINE BIOSCIENCES INC | 33 | Q3 2023 | 7.4% |
CORCEPT THERAPEUTICS INC | 32 | Q3 2023 | 1.2% |
BIOGEN INC | 31 | Q2 2022 | 3.1% |
CONTRAFECT CORP | 30 | Q3 2022 | 1.6% |
YIELD10 BIOSCIENCE INC | 26 | Q3 2023 | 0.6% |
View Birchview Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
SOLENO THERAPEUTICS INC | March 19, 2019 | 742,635 | 2.3% |
YIELD10 BIOSCIENCE, INC. | December 29, 2017 | 186,079 | 2.2% |
HANSEN MEDICAL INC | February 16, 2016 | ? | ? |
METABOLIX, INC. | June 23, 2015 | 749,696 | 2.8% |
View Birchview Capital, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
3/A | 2024-02-20 |
4/A | 2024-02-20 |
SC 13G/A | 2024-02-20 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-08 |
13F-HR | 2023-05-12 |
SC 13G/A | 2023-04-07 |
4 | 2023-03-27 |
3 | 2023-02-13 |
View Birchview Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.